anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy of SUBSYS was demonstrated in a double-blind, placebo-controlled, crossover study in opioid tolerant adult patients with cancer and breakthrough pain. The dose range studied was from 100 mcg per dose to 1600 mcg per dose. Patients entering the trial must have had on average 1-4 episodes of pain per day not controlled on stable, chronic maintenance doses of opioid medication of at least 60 mg/day of morphine, 25 mcg/hr of transdermal fentanyl, or an equianalgesic dose of another opioid for at least 7 days.

The study began with an open-label dose titration period followed by a double-blind treatment period. The goal of titration was to find the dose of SUBSYS that provided adequate analgesia with acceptable side effects. Patients were titrated from a 100 mcg starting dose. Once a successful dose was established, patients were enrolled into the double-blind period and randomized to a sequence of 10 treatments; 7 with SUBSYS and 3 with placebo. 

Patients assessed pain intensity on a 100 mm visual analog scale that rated the pain as 0=none to 100=worst possible pain. With each episode of breakthrough pain, pain intensity was assessed first and then treatment was administered. Pain intensity (0-100) was then measured at 5, 10, 15, 30, 45 and 60 minutes after the start of administration. The summed pain intensity difference from baseline to 30 minutes after dosing was the primary efficacy measure.

Out of 130 patients who entered the titration phase, 98 (75%) were able to titrate to a dose that adequately reduced pain with tolerable side effects and entered into the double-blind period.

The breakdown of successful dose for the patients entering the double-blind period of the study is as follows:

SUBSYS produced a statistically significantly greater reduction in pain intensity compared to placebo as measured by the Summed Pain Intensity Differences scale (SPID) at 30 minutes. 

The primary outcome measure, the mean sum of the pain intensity difference at 30 minutes (SPID30), was statistically significantly higher for SUBSYS than for placebo. The difference in mean pain intensity based on a 100 mm visual analog scale is displayed in Figure 3. 

Figure 3. Pain Intensity Differences over Time
Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
1408925 Dressings IMPERIAL CHEMICAL INDUSTRIES LTD 11 Jan 1973 [14 Feb 1972] 6692/72 Heading A5R [Also in Division Dl] Pad: A pad for administering a medicament comprises a sheet 3 of material provided with fibres 4 in the form of capillary tubes extending through the sheet 3 and projecting from one face thereof for a distance of 20 to 1000 microns. A dressing incorporating the pad comprises a rigid case 1 of metal or plastics material, closed by the sheet 3 so that the fibres 4 projecting outwardly. A reservoir 5 so defined contains the medicament which may be injected through a plug 6. Straps 7 are used to secure the dressing to the skin. The sheet 3 may be intrinsically permeable or be rendered permeable by piercing it in 5 to 10 places. Pressure may be applied to the medicament from a chamber 8 separated from the reservoir 5 by a flexible membrane 9. The chamber 8 may contain polymer-coated sodium bicarbonate granules which liberate carbon dioxide when an acid is injected through a plug 10. Alternatively, the pressure may be applied using a distendible reservoir filled under pressure, a spring-loaded reservoir or a pressure bandage. In an alternative embodiment, the chamber 8 may be omitted. The reservoir may take various forms. For example, it may be a permeable sachet of a plastics material, a foam, a capsule to be pierced before use, a piece of wadding, or a gel. A diffusion layer may be interposed between the reservoir 5 and the pad 3 to control the rate of release of the medication. The diameter of the fibres is 8 to 100 microns and they make an angle of 45 to 90 with the sheet 3. The fibres 4 may be composed of glass, carbon, alumina, zirconia, silicon nitride, nylon, polyparabenzamide or stainless steel. The sheet 3 may be made of plastics or metal although several materials are stated to be suitable. As one example, the medicament may be polypeptides. Method of manufacture: Four methods of forming pads are given. In one example glass capillary tubes 15cm long and 40 microns in diameter are placed 0.5 mm apart, in parallel manner, on a glass plate, with their ends retained on two strips of double sided adhesive tape. A film, 0.5 mm to 1 mm thick, incorporating the tubes is formed by brushing the tubes with a solution in acetone of cellulose acetate containing acetyl triethyl citrate as plasticiser and allowing the solvent to evaporate. Several such films are prepared and cut into 2.5 cm squares whose faces are brushed with acetone and laid on top of each other to form a cube wherein the tubes are aligned in the same direction. The cube is cut with a microtome, transverse to the direction of alignment of the tubes to form sheets about 1 to 2mm thick. One face of the sheet is etched away by brushing it alternately with acetone and water until about 100 microns of the tubes are exposed. Air is blown through the pad during the etching process to avoid blockage of the tubes.
PURPOSE:To obtain a hemolytic streptococcus preparation having increased antitumor activity, by using a hemolytic streptococcus having lowered toxicity, e.g. A-group Streptococcus pyogenes Su strain and treating the strain with a proteinase. CONSTITUTION:The titled preparation can be produced by treating a hemolytic streptococcus having lowered toxicity with a proteinase (e.g. pepsin or trypsin). The hemolytic streptococcus is preferably an attenuated strain, e.g. A-group Streptococcus pyogenes Su strain. The strain is treated with an antibiotic substance (e.g. penicillin G, cephalosporin C or cycloserine) to obtain an attenuated strain (e.g. PCB-45 or OK-432), which is treated with a proteinase at pH0.1-8.0 for 20-50min. The attenuation treatment with the antibiotic substance is carried out by suspending living bacterial cells in a medium containing the antibiotic substance, maintaining the suspension at 30-38 deg.C and heat-treating at 40-50 deg.C.
Opioids are powerful analgesic medications that can reduce pain through action at the mu receptor. Unfortunately, activation of the mu receptor also results in undesirable side effects, such as respiratory depression, sedation, bowel ileus, nausea, itching, and tolerance. Therefore, in order to effectively treat pain with the least amount of opioids required, a multi-modal approach must include medications with different mechanisms of actions at alternative receptors. Some examples of non-narcotic pain medications include acetaminophen (Tylenol), anti-inflammatories (NSAIDS), muscle relaxants, local anesthetics, gabapentinoids (Lyrica), and ketamine, to name a few. In light of the opioid epidemic, medical providers at Vanderbilt University Medical Center (VUMC) are strategically combining these medications in a bundled pain-regimen after surgery. These regimens have been shown to decrease opioid consumption, improve surgical outcomes, and reduce hospital stays, thus coining the term 'enhanced recovery pathway' or enhanced recovery after surgery (ERAS). The combination of these medications has an indisputable synergistic effect. However, it is unknown how each medication contributes individually to the overall efficacy of the pathway. Ultimately, the investigators aim to perform a series of randomized controlled trials in which we isolate each component of the pathway to investigate its effects on length of stay, total opioid consumption, and surgical outcomes. The investigators will begin with studying ketamine.
BACKGROUND: Yokukansan, a traditional Japanese medicine (Kampo), has been widely used to treat neurosis, dementia, and chronic pain. Previous in vitro studies have suggested that Yokukansan acts as a partial agonist of the 5-HT1A receptor, resulting in amelioration of chronic pain through inhibition of nociceptive neuronal activity. However, its effectiveness for treating postoperative pain remains unknown, although its analgesic mechanism of action has been suggested to involve serotonin and glutamatergic neurotransmission. This study aimed to investigate the effect of Yokukansan on postoperative pain in an animal model.
METHODS: A mouse model of postoperative pain was created by plantar incision, and Yokukansan was administered orally the day after paw incision. Pain thresholds for mechanical and heat stimuli were examined in a behavioral experiment. In addition, to clarify the involvement of the serotonergic nervous system, we examined the analgesic effects of Yokukansan in mice that were serotonin-depleted by para-chlorophenylalanine (PCPA) treatment and intrathecal administration of NAN-190, 5-HT1A receptor antagonist.
RESULTS: Orally administered Yokukansan increased the pain threshold dose-dependent in postoperative pain model mice. Pretreatment of para-chlorophenylalanine dramatically suppressed serotonin immunoreactivity in the spinal dorsal horn without changing the pain threshold after the paw incision. The analgesic effect of Yokukansan tended to be attenuated by para-chlorophenylalanine pretreatment and significantly attenuated by intrathecal administration of 2.5 µg of NAN-190 compared to that in postoperative pain model mice without para-chlorophenylalanine treatment and NAN-190 administration.
CONCLUSION: This study demonstrated that oral administration of Yokukansan has acute analgesic effects in postoperative pain model mice. Behavioral experiments using serotonin-depleted mice and mice intrathecally administered with a 5-HT1A receptor antagonist suggested that Yokukansan acts as an agonist at the 5-HT1A receptor, one of the serotonin receptors, to produce analgesia.
The aim of the study is to determine the effects of a short-intensity modified CIMT (mCIMT) program on hand function in stroke patients. This study will be a randomized controlled trial comprising two groups, an experimental group in which patients will be given short-intensity mCIMT along with conventional therapy. A control group, in which participants will be given conventional therapy alone. Patients will be assessed with the Wolf Motor Function Test, the Motor Activity Log, and the Ashworth Scale before and after treatment. The data will be analyzed by using SPSS for windows software version 25. Statistical significance will be set at p=0.05.
Androgenetic alopecia is the most common form of hair loss, affecting up to 50% of men and 21 million women in the US alone. Irrespective of gender, balding is known to influence social interactions and cause substantial emotional distress, especially for those who begin losing their hair at an early age. Topical minoxidil and oral finasteride are currently the only Food and Drug Administration (FDA)-approved therapies for androgenetic alopecia in men, and oral agents are used off-label in women but are contraindicated during pregnancy and lactation. Response to these therapies varies, and they require continued use to maintain the benefits. Hair transplantation surgery is a more permanent, yet costly, solution. All of these treatments carry a risk of undesirable side effects, so there is demand for innovative new therapeutic options. Autologous platelet rich plasma (PRP) injection is a novel therapy for the treatment of patterned hair loss, but no studies to date evaluate different treatment protocols head-to-head. Hence, the purpose of this study is to compare the efficacy of two different PRP treatment schedules (frequency and number of injection sessions) in men and women with androgenetic alopecia.
The invention relates to the field of medicine and in particular relates to silkworm polypeptide 1 with capability of preventing or treating diabetes mellitus. The sequence of the silkworm polypeptide 1 is RLGRRLSEDPATPADQ. A preparation method of the silkworm polypeptide 1 comprises the following steps: (1) decocting; (2) enzymatic hydrolysis; (3) protein separation; (4) semi-preparative RP-HPLC separation and purification; and (5) freeze-drying, wherein papain and alkaline protease are adopted to carry out enzymatic hydrolysis; macroporous resin and sephadex are adopted to carry out protein separation. The invention also relates to application of the silkworm polypeptide 1 in treatment of the diabetes mellitus and complications of the diabetes mellitus. The complications of the diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye disease and diabetic neurologic disorder. Since polypeptide is extracted from silkworm, the silkworm polypeptide 1 disclosed by the invention is good in safety and is capable of effectively preventing or treating the diabetes mellitus.
Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including gene transfer, gene therapy, and gene vaccination. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (mini-Ad vector) and are capable of delivering transgenes and/or heterologous DNA up to 36 kb. The generation and propagation of the mini-Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line. This invention further comprises a methodology for generating a mini-adenoviral (mini-Ad) vector for use in gene therapy of hemophilia and animal test systems for in vivo evaluation of the Ad vectors. More specifically, this invention describes factor VIII (FVIII) Ad vectors that only contain minimal cis-element of the Ad genome (so-called mini-Ad) and comprise a human FVIII cDNA with other supporting DNA elements up to 36 kb. The FVIII mini-Ad can be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also reports designs and methods for producing transgenic mouse models that can be used for in vivo testing the mini-Ad.
Familial Mediterranean fever (FMF) is a self-limiting autoinflammatory disease with well-defined genetic and clinical features. Recurrent episodes of fever and serositis accompanied by increased acute phase reactants and good response to colchicine are the core components of the disease. The frequency of this disease, which is common in Eastern Mediterranean countries, is variable according to regions, but it is reported as 1/1000. In the pathogenesis of the disease, the mutation of the MEFV (Mediterranean Fever) gene, which is located on the 16th chromosome and encodes the pyrin protein, is known as the basic mechanism.In rheumatic diseases, inflammatory mediators cause CS by first creating changes in the regulation of pain in peripheral neurons and then in spinal and supraspinal pathways. Stimulation of peripheral nerves by mediators released during inflammation results in neurogenic inflammation, which is among the peripheral sensitization (PS) mechanisms. PS is defined as the increased sensitivity of nociceptive neurons to normal or below-threshold stimuli and constitutes the first step in the development of CS.Similar to other autoimmune diseases, it is possible that the neuroinflammatory process triggers peripheral and central sensitization mechanisms in FMF patients and affects pain pathways.
Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation, has occurred with the use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Serious hepatotoxicity was reported both by patients receiving high doses for short treatment durations and by patients receiving low doses for long durations.

The hepatic injury has usually, but not always, been reversible upon discontinuation of ketoconazole tablets treatment. Cases of hepatitis have been reported in children.

At baseline, obtain laboratory tests (such as SGGT, alkaline phosphatase, ALT, AST, total bilirubin (TBL), Prothrombin Time (PT), International Normalization Ratio (INR), and testing for viral hepatitides). Patients should be advised against alcohol consumption while on treatment. If possible, use of other potentially hepatotoxic drugs should be avoided in patients receiving ketoconazole tablets.

Prompt recognition of liver injury is essential. During the course of treatment, serum ALT should be monitored weekly for the duration of treatment. If ALT values increase to a level above the upper limit of normal or 30 percent above baseline, or if the patient develops symptoms, ketoconazole treatment should be interrupted and a full set of liver tests should be obtained. Liver tests should be repeated to ensure normalization of values. Hepatotoxicity has been reported with restarting oral ketoconazole (rechallenge). If it is decided to restart oral ketoconazole, monitor the patient frequently to detect any recurring liver injury from the drug.
The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
The invention relates to a bleomycin derivative and an application. Particularly, the invention relates to a compound as shown as Formula I, or pharmaceutically acceptable salt of the compound. Substituents are as described in the specification. The invention further relates to a method of preparing the compound. The method comprises a drug composition of the compound, and an application of the compound in preparing a drug for treating a tumor. The compound is beneficial in treating a breast cancer, a liver cancer, a cervical cancer, a colon cancer, a skin cancer, a lung cancer and the like.
Eligible subjects (104 patients) will receive Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.
A method of using chatbots defined as digital services for personalized support for stress management is provided. A chatbot stimulates conversation with human users. A suite of chatbots is a group of functionally and broadly domain-related multiple chatbots, which nevertheless have different identities and/or different knowledge sub-domains which are presented to the user. The specific stress management addressed herein is related to daily stressors which are defined as daily acute issues such as deadlines or difficult social interactions that can generate perceived stress whose intensity can range from mild to severe. As a routine part of everyday life, these stressors are normally repetitive, and their negative effects can be cumulative if they are not appropriately dealt with in a timely way. The method of using chatbots delivers micro-interventions which lower barriers in time and commitment for users in daily stress management.
The present invention relates to a deficiency-cold anal-gut pill which is searched and studied according to a traditional Chinese medicine theory. The present invention is used for curing deficiency-cold hemorrhoids, anal fistula and archoptoma and is a radical formula with internal administration. The present invention is prepared from psoralea fruit, white tuckahoe, myrrh and centipede according to the proportion of 18 to 9 to 5 to 3 to 1. The psoralea fruit, the white tuckahoe, the myrrh and the centipede are uniformly mixed according to a certain amount and are prepared into a water-paste pill by yellow wine. 6 g of chronic nephritis pills are taken by an adult each time and thrice each day. During administration, raw and cold food, wine and sexual activities are forbidden. The present invention is cautiously used in pregnancy.
The investigators propose a church-based health promotion program designed to reduce colon cancer risk in a mostly African American community served by the Lincoln Memorial Church in South Los Angeles. The Los Angeles County of Public Health has divided the county into nine service planning areas (SPAs), of which South LA is one. Of all the SPAs, the South LA SPA has the highest prevalence of obesity and the lowest adherence to federal nutrition recommendations. With seed grant funds from a cooperative NIH grant shared by the Drew School of Medicine and University of California-Los Angeles (UCLA), the Lincoln Memorial Church of Los Angeles is sponsoring a behavioral intervention featuring 10 weekly sessions composed of cooking demonstrations, brief didactic nutrition education and 10-minute exercise bouts. All sessions will take place in the church kitchen and meeting room. Participants are expected to be 20 mostly African American, overweight/obese community members. The behavioral goal of the health promotion sessions is to encourage participants to eat more fiber-rich plant foods, minimally processed, to consume fewer pro-inflammatory foods including foods rich in saturated fat, sodium and refined sugar, and to engage in federally recommended amounts of physical activity. If research resources become available to enable blood chemistry results and/or fecal metagenomic results, the investigators would predict that 3 months after participant enrollment in the study, participants would experience a reduction in their high-sensitivity-C-reactive protein concentration and an increase in the relative abundance of obligate anaerobic bacteria relative to other bacteria in fecal samples. As seems likely, however, results will be limited to evaluating the weight and form of participant stool samples using the Bristol Stool Chart and evaluating participants' waist circumference and systolic blood pressure. The 3 month follow-up assessment is expected to show increased stool weight, improved Bristol Stool Chart score, decreased waist circumference, decreased systolic blood pressure, reduced intake of saturated fat and refined sugar, and increased weekly physical activity.
This is a retrospective chart review performed at multiple clinics aimed at providing real-world evidence of the use and safety of P4HB products. Adults greater than or equal to 18 years old who have undergone a plastic or reconstructive surgical procedure with P4HB on or after January 1, 2014, will be identified using the centers' medical records. Data on patient demographics, relevant medical history, product and procedure used, product safety, and subjective and objective outcome measures will be collected. The data may be used in publication and education and may inform future product development including future clinical trials. The trial will include all consecutive participants who meet inclusion/exclusion criteria with the goal of having up to 5000 participants. A screening log will be kept at the site of all participants screened regardless of whether or not they were included in the analysis. Participants will be entered into the database based on the consecutive group meeting enrollment criteria.

The overall purpose of this study is to gain an understanding of the use and safety of treatments on a historic collection basis. Hypothesis testing is not necessary for the statistical analyses of the generated data. Broad inclusion criteria with few exclusion criteria are utilized so as to avoid censoring historic real-world use of the device.